Loading organizations...
§ Private Profile · Cambridge, MA, USA
Clinical-stage neuroscience company developing ADHD treatment.
Neurovance has raised $13.3M across 2 funding rounds.
Neurovance has raised $13.3M in total across 2 funding rounds.
Neurovance has raised $13.3M across 2 funding rounds. Most recently, it raised $6.3M Series A Extension in April 2014.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 3, 2014 | $6.3M Series A Plus | — | TIM Barberich, GBS Venture Partners, Hambrecht & Quist Capital Management, H&Q Healthcare Investors, Novartis, State OF Wisconsin Investment Board, Venture Investors | Announced |
| Oct 18, 2012 | $7M Series A | Novartis | TIM Barberich, GBS Venture Partners, H&Q Healthcare Investors, H&Q Life Sciences Investors, State OF Wisconsin Investment Board, Venture Investors | Announced |
Neurovance has raised $13.3M in total across 2 funding rounds.
Neurovance's investors include Tim Barberich, GBS Venture Partners, Hambrecht & Quist Capital Management, H&Q Healthcare Investors, Novartis, State of Wisconsin Investment Board, Venture Investors, H&Q Life Sciences Investors.